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Background/aim: Gestational transient thyrotoxicosis (GTT) is a transient, mild hyperthyroidism that occurs early in pregnancy and
is due to human chorionic gonadotropin. There is no clear information about why only some pregnant women develop GTT. Previous
papers stated that vitamin D plays a role in thyroid functions. We aimed to evaluate the relationship between vitamin D and GTT.
Materials and methods: Fifty-three patients diagnosed with GTT at the 6th to 10th weeks of gestation were included in the study (GTT
group). Thirty-five pregnant women with normal thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine
(fT4) levels served as a control group. Vitamin D, TSH, fT3, and fT4 levels were followed during entire the pregnancy.
Results: TSH levels had been normalized at the 20th week of gestation in all patients with GTT (mean TSH: 0.56 ± 0.2 µIU/mL).
Vitamin D levels were significantly lower in the GTT group than the controls (11.1 ± 7.7 and 16.5 ± 0.5 ng/mL, respectively; P = 0.008).
Conclusion: Pregnant women who are diagnosed with GTT should be evaluated for possible vitamin D deficiency.
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1. Introduction
Thyroid hormone physiology changes during pregnancy.
Following conception, levels of human chorionic
gonadotropin (hCG), which is structurally homologous
to thyroid-stimulating hormone (TSH), increase. hCG has
a stimulatory role on thyroid follicular cells by activating
TSH receptors, which results in an increase in serum
total and free thyroxine concentrations, and this increase
causes a slight reciprocal decrease in circulating serum
TSH levels. These effects are maximum at the end of the
first trimester, at which time hCG levels peak (1,2). This
situation is known as gestational transient thyrotoxicosis
(GTT), which is diagnosed after excluding other causes
of hyperthyroidism, including Graves’ disease and toxic
nodular goiter. While incidence of developing “true”
hyperthyroidism during pregnancy due to any cause is
about 0.05% (3), the incidence of GTT is about 2%–11%
(4–6).
The classical main function of vitamin D (vit D) is
regulation of calcium homeostasis (7). In addition, vit D
also plays roles that affect the immune, cardiovascular,
and metabolic systems (8–11). Vitamin D deficiency is
very common all over the world (12). The relationship
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between vit D and thyroid hormone biosynthesis is not
clear. Previous studies revealed that vit D modulated
pituitary TSH secretion by using specific binding sites
(13). Low levels of vit D may contribute to autoimmune
thyroid diseases, and vit D replacement treatment may
suppress autoimmune reaction and reduce serum thyroid
autoantibody levels (14).
Maternal thyroid hormones play an important role in
fetal development and thyroid disorders are associated
with several gestational complications and perinatal
outcomes (15).
Although vitamin D deficiency is common in pregnant
women in the literature, to our knowledge, there is no
publication about the relationship between GTT and vit
D. In this study we aimed to investigate the relationship
between vit D and GTT during pregnancy.
2. Materials and methods
Fifty-three patients diagnosed with GTT in the 6th to 10th
weeks of gestation who had applied to our endocrinology
outpatient clinics between April 2014 and June 2014 were
included in this study as the GTT group. GTT without
thyroid disease was diagnosed when low or undetectable
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serum TSH levels and normal or elevated serum T4
levels were present with normal antithyroid peroxidase
antibodies (anti-TPO), antithyroglobulin antibodies (antiTg), and TSH receptor antibodies levels (1,2). Thirty-five
pregnant women with TSH, free triiodothyronine (fT3),
free thyroxine (fT4), and TSH receptor antibody levels
within normal limits and normal thyroid findings on
ultrasonography served as the control group.
Pregnant women with a history of neck radiotherapy,
thyroid disease, thyroid hemiagenesis, hydatidiform
moles, choriocarcinoma, or vit D replacement therapy in
the last 12 months were excluded. All of the participants
in the two groups had similar habits of dressing. All of the
patients were followed until the end of the pregnancy on a
monthly basis in terms of thyroid functions.
Fasting blood samples were obtained, after an overnight
fast, between 0800 and 0900 hours for serum 25-OH vit D,
TSH, fT4 and fT3, inorganic phosphorus (P), total calcium
(Ca), parathyroid hormone (PTH), anti-TPO, anti-Tg,
TSH receptor antibodies, and hCG assays. Vitamin D
deficiency or insufficiency was defined as vit D levels of
<20 ng/mL or as 20 to 29.9 ng/mL, respectively. Serum
Ca and P were assayed photometrically on an AU5800
analyzer (Beckman Coulter, USA). PTH was assayed with
the Elecsys 1010 System (Roche, Manheim, Germany).
Serum 25-OH vit D levels were quantified by liquid
chromatography–mass spectrometry (LC-MS/MS) on
Waters analyzers (Acquity UPLC and Quattro Premier XE
Micromass Spectrometry, USA). TSH, fT4, fT3, anti-TPO,
and anti-Tg levels; TSH receptor antibodies; and hCG were
determined by using a chemiluminescent immunoassay
(Cobas E6000, Roche Diagnostic, Germany). The patients
with low vit D levels (vit D <20 ng/dL) received a daily
supplement of 1000 IU cholecalciferol for 3 months and vit
D levels were reassayed after replacement.

Patients were also questioned about hyperemesis
gravidarum. We used persistent vomiting accompanied
by weight loss exceeding 5% of prepregnancy body weight
and ketonuria unrelated to other causes as criteria for the
diagnosis of hyperemesis (16).
Ultrasonography examinations of the patients were
performed in our clinic by an endocrinologist using Aplio
500 (Toshiba Medical Systems Corporation, Otawara,
Japan) USG equipment with a 14-MHz linear probe.
This study was approved by the local ethics committee.
Informed consent forms in accordance with the
Declaration of Helsinki 2013 Brazil version were obtained
from all subjects who volunteered to be included in the
study.
2.1. Statistical analysis
Statistical analysis was performed using IBM SPSS 20.0
(IBM Corp., Armonk, NY, USA). The suitability of the
normal distribution of the data was determined with the
Shapiro–Wilk test. Two independent samples t-tests and
Mann–Whitney U tests were used for comparisons between
the groups for quantitative variables. The chi-square test
was used for qualitative variables. Data were expressed
as frequency and percentage or mean and standard error.
Spearman’s correlation test was used to investigate the
association between two continuous variables. P < 0.05
was considered as statistically significant.
3. Results
The characteristics of the pregnant women are presented
in Table 1. The two groups were similar with regard to age,
body mass index, and gestational week at entry into the
study. No patient in either group had a multiple pregnancy.
Laboratory findings of the two groups are summarized in
Table 2. The mean TSH levels were lower and fT3 and fT4

Table 1. The characteristics of the pregnant women.
Parameter

GTT group (n = 53)

Control group (n = 35)

P

Age (years)

28.7 ± 5.1

26.6 ± 5.1

0.07

Height (cm)

159.8 ± 5.4

159.4 ± 5.2

0.70

Weight (kg)

62.9 ± 9.9

63.0 ± 12.0

0.95

BMI (m /kg)

24.5 ± 4.2

25.0 ± 5.3

0.64

Week of pregnancy

9.4 ± 1.1

9.1 ± 2.0

0.60

Normal

28 (53%)

35 (100%)

0.001

Diffuse goiter

4 (7%)

0 (0%)

0.98

Nodular goiter

19 (36%)

0 (0%)

0.79

Thyroiditis

2 (4%)

0 (0%)

0.62

2

Thyroid USG
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Table 2. Laboratory findings of the groups.
6th to 10th gestational weeks

38th to 42nd gestational weeks

Parameter

GTT group
(n =53)

Control group
(n =35)

P

GTT group
(n =53)

Control group
(n =35)

P

TSH (0.27–4.2 µIU/mL)

0.01 ± 0.0

1.7 ± 0.7

<0.001

1.3 ± 0.3

1.6 ± 0.4

0.08

fT3 (2.1–4.4 pg/mL)

3.4 ± 0.7

2.8 ± 0.4

<0.001

2.6 ± 0.6

2.7 ± 0.3

0.69

fT4 (0.8–2.7 ng/dL)

1.4 ± 0.3

1.0 ± 0.1

<0.001

1.1 ± 0.2

1.0 ± 0.1

0.37

Vitamin D (19–57.6 ng/mL)

11.1 ± 7.7

16.5 ± 0.5

0.008

32.5 ± 4.4

31.8 ± 3.6

0.07

Total calcium (8.4–10.6 mg/dL)

9.2 ± 0.5

9.1 ± 0.4

0.72

9.1 ± 0.2

9.2 ± 0.5

0.68

Phosphorus (2.5–4.6 mg/dL)

2.9 ± 0.2

3.1 ± 0.1

0.86

2.7 ± 0.3

2.9 ± 0.2

0.84

PTH (10–65 pg/mL)

34 ± 4.3

28 ± 3.4

0.67

36 ± 2.1

34 ± 3.3

0.77

Bolded P-values indicate statistical significance (P < 0.05).

levels were significantly higher (P < 0.001 for all) in the
GTT group than the controls. All patients in both groups
had fT3 and fT4 levels within normal limits. Anti-TPO
and anti-Tg were positive in 13.6% and 9.6% of the control
group, respectively. Vitamin D levels were significantly
lower in the GTT group than the controls (P = 0.008).
TSH levels had normalized at the 20th week of
gestation in all patients with GTT and mean TSH level was
0.56 ± 0.2 µIU/mL. Mean week for normalization of TSH
was 15 ± 1.3 weeks of gestation (Figure). No one in the
control group had abnormal TSH, fT3, or fT4 levels during
pregnancy.
When all of women were considered in terms of vit
D levels, 84.9% of women in the GTT group population
were vit D deficient, 11.3% were vit D insufficient, and
3.7% were vit D sufficient with serum concentrations
above 30 ng/mL. In the control group, 57.1% were vit D
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Figure. The mean TSH levels during pregnancy in the GTT
group and the control group (CG).
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deficient, 34.2% were vit D insufficient, and 8.5% were vit
D sufficient with serum concentrations above 30 ng/mL.
After 3 months of vit D supplementation, mean serum
vit D levels were increased to 32.5 ng/dL and 31.8 ng/dL
in the GTT and control groups, respectively. There were
no statistically significant differences among vit D, Ca, P,
and PTH between the two groups in the 3rd trimester (P
> 0.05).
There were no statistically significant differences
between groups in terms of TSH, fT3, or fT4 levels when
all patients were divided into two groups as those with vit
D levels below or above 20 ng/mL (P > 0.05).
We assayed hCG at the 6th to 10th weeks of gestation
in both groups. Mean hCG level was significantly higher
in the GTT group than the controls (124.254 ± 10.516 vs.
102.865 ± 11.284 mIU/mL, respectively; P < 0.05).
Hyperemesis gravidarum was diagnosed two patients
in the GTT group and one woman in the control group.
There was no correlation between vit D and any of
the other parameters (TSH, fT3, fT4, and hCG levels) in
either the GTT group or the control group (P > 0.05). In
the GTT group, there were negative correlations between
gestational week and both fT3 and fT4 (r = –48.4, P <
0.001 and r = –40.0, P = 0.004, respectively).
There was no statistically difference between groups
with regard to abnormal ultrasonography findings (P >
0.05).
4. Discussion
To the best of our knowledge, this is the first study that
showed the pregnant women who had GTT had lower
vit D levels than the euthyroid pregnant group. In the
literature, research predominantly shows that vit D affects
thyroid autoimmunity. However, the relationship between
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vit D and TSH levels cannot be explained by autoimmunity
as it does not play a role in GTT pathophysiology.
Interaction between thyroid hormones and vit D
was not explained completely. Both vit D and thyroid
hormone bind to similar steroid hormone receptors. Sar
et al. suggested a central effect of vit D on the modulation
of thyrotropin secretion in the pituitary gland (13).
Administration of vit D has been reported to increase
thyrotropin-releasing hormone-induced TSH secretion
in rats (17). In another study, vit D level was increased
after administration of T3, T4, and TSH in rats (18).
In addition, the current literature shows that vit D is
deficient in both hypo- and hyperthyroidism. However,
these results are contradictory and inconclusive (19–22).
Bouillon et al. also revealed that 1,25-dihydroxyvitamin
D3 levels were low in patients with hyperthyroidism,
although 1,25-dihydroxyvitamin D3 levels were high in
patients with hypothyroidism (21). Hyperthyroidism may
cause low vit D due to the increasing of vit D metabolism.
Rosskamp et al. revealed that after thyrotropin-releasing
hormone injections, there was no change in serum vitamin
D metabolites, calcium, and phosphorus (23). It has been
recently demonstrated that vitamin D-receptor gene
and vitamin D-binding protein gene polymorphisms are
associated with Graves’ disease (21,24). Vitamin D levels
may effect pituitary cells and/or thyrocytes and VDR gene
mutations may affect thyroid function.

Vitamin D deficiency is a widespread disorder seen
in approximately 30% to 50% of the adult population
(25,26). It is generally due to a lack of adequate sunlight
exposure and/or nutritional vit D intake (27). Vitamin
D deficiency and insufficiency are present in 74.9% and
13.8% of the Turkish population, respectively (28), and
vit D deficiency was revealed in 37%–50% of pregnancies.
This ratio may change depending on living conditions and
ethnicity (29,30). Pehlivan et al. showed that vit D levels
were mostly below 25 ng/mL in pregnant Turkish women
(31). We revealed that >90% our study population had
vit D deficiency or insufficiency, which could be related
to pregnancy due to placental transition (32) and less
exposure to direct sunlight due to dressing habits, or less
sunny geographical regions.
Limitations of our study were the small sample size and
all participants being from the same region with similar
dressing habits and the same ethnicity, which can all affect
vit D levels. We supplemented vit D for all participants due
to ethical reasons. Therefore, we could not evaluate the
effects of vit D on thyroid functions.
In conclusion, in this study, we have found lower vit
D levels in pregnant patients with GTT than in euthyroid
pregnancies. Pregnant women who are diagnosed with
GTT should be evaluated for possible vitamin D deficiency.
Further studies are needed to assess the role of vitamin D
on GTT.
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